使用Nanodropper给药的0.5%马来酸噻吗洛尔微滴的疗效与安全性评估
这项前瞻性、非劣效性、平行、多中心、单盲、阳性对照、随机试验在Aravind眼科系统纳入新诊断的原发性开角型青光眼(OAG)和高眼压症(OHT)初治受试者,比较12.5 μl马来酸噻吗洛尔0.5%微滴(Nanodropper适配器)与常规28 μl滴眼液的眼压(IOP)降幅。结果显示微滴与常规滴眼液在所有时间点均较基线显著降低IOP,4个时间点中3个达到非劣效性;微滴组静息心率下降较常规滴眼液组约少3次/分。作者认为噻吗洛尔微滴的降眼压作用似乎与常规滴眼液相当,对静息心率和血压的影响略减弱。
要点
- 微滴与常规滴眼液在所有时间点均较基线显著降低IOP,4个时间点中3个达到非劣效性。
- 微滴组静息心率下降较常规滴眼液组约少3次/分。
- 作者认为微滴降眼压作用似乎与常规滴眼液相当,对静息心率和血压影响略减弱。
核心结论
- 作者认为噻吗洛尔微滴的降眼压作用似乎与常规滴眼液相当,对静息心率和血压的影响略减弱。
研究设计与样本
- 前瞻性、非劣效性、平行、多中心、单盲、阳性对照、随机试验。
- 受试者为Aravind眼科系统新诊断的OAG和OHT初治受试者。
- 受试者双眼接受1滴市售滴眼液或1微滴马来酸噻吗洛尔0.5%。
主要发现
- 微滴与常规滴眼液在所有时间点均较基线显著降低IOP。
- 非劣效性在4个时间点中的3个成立。
- 微滴组静息心率下降较常规滴眼液组约少3次/分。
关键数值与推荐
- 主要结局指标为IOP;次要结局为静息心率、收缩压和舒张压。
- 在基线及给药后1、2、5、8小时测量IOP、静息心率和血压。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine if 12.5 μl timolol maleate 0.5% microdrops dispensed with the Nanodropper Adaptor provide noninferior intraocular pressure (IOP) reduction compared with conventional 28 μl drops in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). DESIGN: Prospective, noninferiority, parallel, multicenter, single-masked, active-controlled, randomized trial. PARTICIPANTS: Treatment-naïve subjects who were recently diagnosed with OAG and OHT at the Aravind Eye Care System. METHODS: Both eyes of subjects received 1 commercially available drop or both eyes of subjects received 1 microdrop of timolol maleate 0.5%. We measured IOP, resting heart rate (HR), and blood pressure (BP) at baseline and 1, 2, 5, and 8 hours after timolol administration. MAIN OUTCOME MEASURES: The IOP was the primary outcome measure. Secondary outcomes were resting HR, systolic BP (sBP), and diastolic BP (dBP). RESULTS: Adaptor-mediated microdrops and conventional drops of timolol significantly decreased IOP compared with baseline at all timepoints. Noninferiority was established at 3 of 4 timepoints. Heart rate decreases with Nanodropper were approximately 3 beats per minute (bpm) less than with conventional drops. CONCLUSIONS: Timolol microdrops appear to be as effective in ocular hypotensive action as conventional drops with a slightly attenuated effect on resting HR and BP. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Steger JS, Durai I, Odayappan A, et al. An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper. Ophthalmology. 2024. PMID: 38492865. doi:10.1016/j.ophtha.2024.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。